Published in Vaccine Weekly, March 16th, 2005
Revenues for the full year 2004 were $14.5 million compared with $8.1 million for the full year 2003. Results for the year reflected higher contract revenues for DNA vaccine supplies, a milestone payment under the company's agreement with Centelion SAS, formerly Gencell SAS, a wholly owned subsidiary of Aventis Pharma SA, and increased grant funding for the company's cytomegalovirus (CMV) vaccine...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly